WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2025)
Top diagnostic & research stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research
Overview
Zen RatingPriceValueGrowthFinancialsMomentumSentimentForecastDividendsDue Diligence
B
Diagnostics & Research is Zen Rated B and is the 47th ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Exchange
Industry
Zen Rating
Market Cap
Price
1d %
EBITDA
P/E
D/E
Country
DD Score
SHC
SOTERA HEALTH CO
NASDAQ
Diagnostics & Research
$5.03B$17.700.00%$428.10M88.50x4.79
United States
IDXX
IDEXX LABORATORIES INC
NASDAQ
Diagnostics & Research
$54.98B$688.480.04%$1.45B54.13x1.17
United States
A
AGILENT TECHNOLOGIES INC
NYSE
Diagnostics & Research
$39.23B$138.390.05%$1.84B30.15x0.89
United States
DHR
DANAHER CORP
NYSE
Diagnostics & Research
$162.69B$230.32-0.50%$6.87B47.20x0.56
United States
TMO
THERMO FISHER SCIENTIFIC INC
NYSE
Diagnostics & Research
$218.19B$580.740.28%$11.28B33.49x1.02
United States
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
NYSE
Diagnostics & Research
$10.02B$203.660.25%$513.77M-133.99x1.19
United States
NEOG
NEOGEN CORP
NASDAQ
Diagnostics & Research
$1.55B$7.13-0.14%-$879.32M-1.49x0.59
United States
IQV
IQVIA HOLDINGS INC
NYSE
Diagnostics & Research
$38.58B$226.920.40%$3.43B30.92x3.64
United States
CDNA
CAREDX INC
NASDAQ
Diagnostics & Research
$1.00B$19.48-1.27%$70.49M16.65x0.39
United States
LH
LABCORP HOLDINGS INC
NYSE
Diagnostics & Research
$21.05B$253.89-0.22%$2.21B24.77x1.10
United States
QGEN
QIAGEN NV
NYSE
Diagnostics & Research
$9.88B$45.37-0.24%$731.11M24.39x0.80
Netherlands
PRE
PRENETICS GLOBAL LTD
NASDAQ
Diagnostics & Research
$234.55M$16.88-0.18%N/A-4.73x0.22
Hong Kong
BNR
BURNING ROCK BIOTECH LTD
NASDAQ
Diagnostics & Research
$228.14M$21.18-0.17%N/A-12.89x0.48
China
ILMN
ILLUMINA INC
NASDAQ
Diagnostics & Research
$20.62B$134.95-0.27%$1.27B30.19x1.59
United States
CAI
CARIS LIFE SCIENCES INC
NASDAQ
Diagnostics & Research
$7.97B$28.24-0.02%N/AN/A1.06
United States
FLGT
FULGENT GENETICS INC
NASDAQ
Diagnostics & Research
$825.98M$26.72-1.07%-$21.75M-19.22x0.08
United States
MEDP
MEDPACE HOLDINGS INC
NASDAQ
Diagnostics & Research
$15.99B$567.56-0.75%$563.19M38.71x4.97
United States
FONR
FONAR CORP
NASDAQ
Diagnostics & Research
$95.17M$14.45-0.55%$14.14M12.79x0.33
United States
BLLN
BILLIONTOONE INC
NASDAQ
Diagnostics & Research
$4.09B$89.303.43%N/AN/A-0.62
United States
WAT
WATERS CORP
NYSE
Diagnostics & Research
$22.98B$386.060.32%$1.04B35.39x1.09
United States
MYGN
MYRIAD GENETICS INC
NASDAQ
Diagnostics & Research
$604.02M$6.48-1.07%-$353.20M-1.50x0.95
United States
DGX
QUEST DIAGNOSTICS INC
NYSE
Diagnostics & Research
$19.57B$175.940.01%$2.10B20.36x1.23
United States
MTD
METTLER TOLEDO INTERNATIONAL INC
NYSE
Diagnostics & Research
$29.01B$1,420.100.21%$1.23B35.34x-15.13
United States
ACRS
ACLARIS THERAPEUTICS INC
NASDAQ
Diagnostics & Research
$328.29M$3.03-0.33%-$141.19M-1.92x0.46
United States
NEO
NEOGENOMICS INC
NASDAQ
Diagnostics & Research
$1.59B$12.28-0.16%-$32.65M-13.95x0.64
United States
GH
GUARDANT HEALTH INC
NASDAQ
Diagnostics & Research
$12.98B$102.980.59%-$354.11M-32.08x-4.60
United States
CSTL
CASTLE BIOSCIENCES INC
NASDAQ
Diagnostics & Research
$1.15B$39.40-1.73%$24.00M-96.09x0.21
United States
XGN
EXAGEN INC
NASDAQ
Diagnostics & Research
$138.92M$6.13-0.97%-$12.56M-6.66x2.46
United States
ICLR
ICON PLC
NASDAQ
Diagnostics & Research
$13.96B$182.84-0.46%$1.21B24.64x0.77
Ireland
GRAL
GRAIL INC
NASDAQ
Diagnostics & Research
$3.57B$91.59-0.29%-$388.10M-8.58x0.16
United States
RDNT
RADNET INC
NASDAQ
Diagnostics & Research
$5.64B$73.150.29%$268.98M-430.29x2.22
United States
RVTY
REVVITY INC
NYSE
Diagnostics & Research
$10.97B$96.75-0.03%$775.92M48.62x0.65
United States
BDSX
BIODESIX INC
NASDAQ
Diagnostics & Research
$54.26M$6.820.00%-$26.13M-1.27x-52.52
United States
NTRA
NATERA INC
NASDAQ
Diagnostics & Research
$32.26B$233.74-0.76%-$249.43M-102.07x0.46
United States
MYNZ
MAINZ BIOMED NV
NASDAQ
Diagnostics & Research
$5.20M$1.278.55%-$18.40M-0.23x2.89
Germany
TWST
TWIST BIOSCIENCE CORP
NASDAQ
Diagnostics & Research
$2.02B$33.05-1.58%-$52.12M-25.42x0.36
United States
OPK
OPKO HEALTH INC
NASDAQ
Diagnostics & Research
$990.33M$1.29-0.77%$45.18M-5.38x0.53
United States
MDXH
MDXHEALTH SA
NASDAQ
Diagnostics & Research
$16.88M$3.41-1.73%-$2.60M-0.67x-19.67
Belgium
IMDX
INSIGHT MOLECULAR DIAGNOSTICS INC
NASDAQ
Diagnostics & Research
$182.59M$6.379.45%-$58.47M-1.99x-5.78
United States
NOTV
INOTIV INC
NASDAQ
Diagnostics & Research
$20.93M$0.61-4.55%$24.75M-0.29x4.67
United States
PSNL
PERSONALIS INC
NASDAQ
Diagnostics & Research
$722.87M$8.14-3.21%-$62.03M-9.81x0.42
United States
PRPH
PROPHASE LABS INC
NASDAQ
Diagnostics & Research
$2.40M$0.52-15.45%-$18.11M-0.03x8.58
United States
DRIO
DARIOHEALTH CORP
NASDAQ
Diagnostics & Research
$67.95M$10.040.00%-$36.24M-0.90x0.57
Israel
STIM
NEURONETICS INC
NASDAQ
Diagnostics & Research
$97.25M$1.420.00%-$33.50M-1.71x4.17
United States
NDRA
ENDRA LIFE SCIENCES INC
NASDAQ
Diagnostics & Research
$5.93M$5.08-0.39%-$7.84M0.26x10.46
United States
BIAF
BIOAFFINITY TECHNOLOGIES INC
NASDAQ
Diagnostics & Research
$5.26M$1.17-4.88%-$14.11M-0.06x0.30
United States
LAB
STANDARD BIOTOOLS INC
NASDAQ
Diagnostics & Research
$530.70M$1.38-6.12%-$107.13M-4.18x0.35
United States
SERA
SERA PROGNOSTICS INC
NASDAQ
Diagnostics & Research
$135.85M$3.52-2.22%-$31.13M-4.57x0.32
United States
XWEL
XWELL INC
NASDAQ
Diagnostics & Research
$3.56M$0.62-1.90%-$13.29M-0.18x-2.90
United States
BNBX
BNB PLUS CORP
NASDAQ
Diagnostics & Research
$10.17M$2.330.43%-$15.46M-0.02x1.08
United States
ISPC
ISPECIMEN INC
NASDAQ
Diagnostics & Research
$3.73M$0.38-1.55%-$9.69M-0.05x1.93
United States
ADVB
ADVANCED BIOMED INC
NASDAQ
Diagnostics & Research
$7.94M$0.37-2.13%-$3.09M-2.29x1.08
United States
VNRX
VOLITIONRX LTD
NYSEMKT
Diagnostics & Research
$30.70M$0.25-0.79%-$21.14M-1.09x-1.22
United States
MBAI
CHECK-CAP LTD
NASDAQ
Diagnostics & Research
$9.83M$1.68-6.15%-$25.79M-0.39x-1.26
Israel
TRIB
TRINITY BIOTECH PLC
NASDAQ
Diagnostics & Research
$18.47M$1.00-1.96%-$22.42M-0.67x-3.01
Ireland
EXAS
EXACT SCIENCES CORP
NASDAQ
Diagnostics & Research
$19.24B$101.570.03%-$710.69M-18.99x1.36
United States
PRPO
PRECIPIO INC
NASDAQ
Diagnostics & Research
$41.63M$23.76-0.53%$490.00k-28.63x0.54
United States
1

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Dec 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Sotera Health Co (NASDAQ:SHC)


Sotera Health Co (NASDAQ:SHC) is the #1 top diagnostic & research stock out of 57 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: C, Growth: A, Momentum: C, Sentiment: C, Safety: B, Financials: B, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 24, which is -2 points lower than the diagnostic & research industry average of 26. Although this number is below the industry average, our proven quant model rates SHC as a "A".

SHC passed 8 out of 33 due diligence checks and has weak fundamentals. Sotera Health Co has seen its stock return 31.01% over the past year, overperforming other diagnostic & research stocks by 15 percentage points.

Sotera Health Co has an average 1 year price target of $18.00, an upside of 1.69% from Sotera Health Co's current stock price of $17.70.

Sotera Health Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Sotera Health Co, 25% have issued a Strong Buy rating, 25% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Idexx Laboratories (NASDAQ:IDXX)


Idexx Laboratories (NASDAQ:IDXX) is the #2 top diagnostic & research stock out of 57 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Idexx Laboratories (NASDAQ:IDXX) is: Value: C, Growth: C, Momentum: B, Sentiment: C, Safety: C, Financials: A, and AI: B.

Idexx Laboratories (NASDAQ:IDXX) has a Due Diligence Score of 50, which is 24 points higher than the diagnostic & research industry average of 26.

IDXX passed 17 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock return 65.06% over the past year, overperforming other diagnostic & research stocks by 49 percentage points.

Idexx Laboratories has an average 1 year price target of $751.25, an upside of 9.12% from Idexx Laboratories's current stock price of $688.48.

Idexx Laboratories stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Idexx Laboratories, 62.5% have issued a Strong Buy rating, 12.5% have issued a Buy, 25% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Agilent Technologies (NYSE:A)


Agilent Technologies (NYSE:A) is the #3 top diagnostic & research stock out of 57 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Agilent Technologies (NYSE:A) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: A, Financials: B, and AI: C.

Agilent Technologies (NYSE:A) has a Due Diligence Score of 46, which is 20 points higher than the diagnostic & research industry average of 26.

A passed 17 out of 38 due diligence checks and has strong fundamentals. Agilent Technologies has seen its stock return 1.88% over the past year, underperforming other diagnostic & research stocks by -14 percentage points.

Agilent Technologies has an average 1 year price target of $169.33, an upside of 22.36% from Agilent Technologies's current stock price of $138.39.

Agilent Technologies stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Agilent Technologies, 75% have issued a Strong Buy rating, 8.33% have issued a Buy, 16.67% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.36%, which is 1 percentage points higher than the diagnostic & research industry average of 0.66%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 27.2% indicates that its dividend yield is sustainable for the long-term.

2. Labcorp Holdings (NYSE:LH)


Labcorp Holdings (NYSE:LH) has an annual dividend yield of 1.13%, which is the same as the diagnostic & research industry average of 0.66%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 28.1% indicates that its dividend yield is sustainable for the long-term.

3. Agilent Technologies (NYSE:A)


Agilent Technologies (NYSE:A) has an annual dividend yield of 0.54%, which is the same as the diagnostic & research industry average of 0.66%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 21.6% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.01% in the last day, and up 0.69% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Qiagen Nv (NYSE:QGEN)


Qiagen Nv (NYSE:QGEN) is the most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 29, which is 15 points higher than the diagnostic & research industry average of 14. It passed 2 out of 7 valuation due diligence checks.

Qiagen Nv's stock has gained 0.8% in the past year. It has underperformed other stocks in the diagnostic & research industry by -15 percentage points.

2. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Fonar has a valuation score of 71, which is 57 points higher than the diagnostic & research industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has dropped -5.56% in the past year. It has underperformed other stocks in the diagnostic & research industry by -22 percentage points.

3. Revvity (NYSE:RVTY)


Revvity (NYSE:RVTY) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Revvity has a valuation score of 14, which is 0 points higher than the diagnostic & research industry average of 14. It passed 1 out of 7 valuation due diligence checks.

Revvity's stock has dropped -14% in the past year. It has underperformed other stocks in the diagnostic & research industry by -30 percentage points.

Are diagnostic & research stocks a good buy now?

53.49% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 6.86% over the next year.

2.13% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 27.66% of diagnostic & research stocks are rated B (Buy), 63.83% are rated C (Hold), 6.38% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 22.52x.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.